Tradestie Institutional Equity Comparison Engine
ICCC vs ENTX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ICCC Overall Edge
ICCC Captures Institutional Edge (3โ1 Pillars ยท 6โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Immucell Corp (ICCC) driven by superior Valuation, Growth & Margin, Momentum & Technical while ENTX counters with relative strength in Options & Structure. Fundamentally, ICCC trades at N/M Forward P/E with 15.2% operating margin (+11.5% YoY revenue) versus ENTX at N/M Forward P/E and 0.0% operating margin (-100.0% YoY). In options structure, ICCC sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ENTX sits in CONSOLIDATION (32nd %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
ICCC
ICCC N/M vs ENTX N/M Fwd P/E
Growth & Margin Winner
ICCC
Op Margin 15.2% vs 0.0% ยท YoY +11.5% vs -100.0%
Momentum & Technical Winner
ICCC
1Y +88.8% vs +10.2% ยท 52W Pos 91% vs 64%
Options & Structure Winner
ENTX
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (32nd %ile IV)
ICCC
NASDAQ
Immucell Corp
In Vitro & In Vivo Diagnostic Substances
$11.42
+6.23% 1D
Market Cap
$97.7M
1M Return
+6.23%
1Y Return
+88.76%
Forward P/E
N/M
Unified AI Score
43.8 / 100
HOLD
Tech 15.0
Fund 48.0
Flow 50.0
Mom 50.0
ENTX
NASDAQ
Entera Bio Ltd. Ordinary Shares
Biological Products, (No Disgnostic Substances)
$3.02
-2.89% 1D
Market Cap
$541.6M
1M Return
+12.69%
1Y Return
+10.22%
Forward P/E
N/M
Unified AI Score
53.9 / 100
HOLD
Tech 37.0
Fund 54.0
Flow 72.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ICCC +88.76%
ENTX +10.22%
Spread: +78.54 pp (ICCC Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ICCC Revenue | ENTX Revenue | ICCC Op. Margin | ENTX Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $10M | N/A | -13.2% | N/A | ICCC |
| FY2019 | $10M | N/A | -7.0% | N/A | ICCC |
| FY2020 | $20M | $0M | -9.0% | -3059.7% | ICCC |
| FY2021 | $20M | $0M | 1.3% | -2139.6% | ICCC |
| FY2022 | $20M | $0M | -12.4% | -9714.2% | ICCC |
| FY2023 | $20M | N/A | -32.9% | N/A | ICCC |
| FY2024 | $30M | $0M | -6.2% | -5295.6% | ICCC |
| FY2025 | $30M | $0M | 6.0% | -27450.0% | ICCC |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ICCC | ENTX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $97.7M | $541.6M | Larger Scale | ENTX |
| Trailing P/E Ratio Valuation | 56.6x | N/M | Lower Multiple | ICCC |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +11.5% | -100.0% | Higher Growth | ICCC |
| Operating Margin (TTM) Profitability | 15.2% | 0.0% | Higher Margin | ICCC |
| Net Profit Margin Profitability | 2.6% | 0.0% | Higher Margin | ICCC |
| Return on Equity (ROE) Capital Efficiency | 2.6% | -20.3% | Higher ROE | ICCC |
| 52-Week Range Position Momentum | 91% ($5โ$12) | 64% ($1โ$4) | Stronger Trend | ICCC |
| Beta / 30D Volatility Risk Regime | 0.24ฮฒ ยท 46% Vol | 1.07ฮฒ ยท 46% Vol | Lower Realized Risk | ENTX |
| Unified Institutional Score Composite Signal | 43.8 / 100 (HOLD) | 53.9 / 100 (HOLD) | Higher Composite | ENTX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ICCC vs ENTX Buy Guide
ICCC
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
ENTX
CONSOLIDATION
79d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
32nd %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ICCC nor ENTX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.